Section IV. Drug Resistance and Metabolism Gene Therapy
Published in Gene Therapy of Cancer
Section III. Immunotherapeutics
Published in Gene Therapy of Cancer
Copyright
Published in Gene Therapy of Cancer
Oncolytic Adenoviruses in the Treatment of Cancer in Humans11Conflict of interest: O.H. and A.H. are shareholders in Onc...
Published in Gene Therapy of Cancer
After a century of volatile interest in treating tumors with viruses, adenovirus has been used increasingly for the past century to treat cancer patients. Technical innovations have led to the production of safer oncolytic viruses, which can also be armed to make them more potent. In this chapter, ways of making the treatments more effective are de...
Reoviral Therapy for Cancer
Published in Gene Therapy of Cancer
Reovirus type 3 Dearing (Reolysin, Oncolytics Biotech) is a wild-type double-stranded RNA virus that is ubiquitous and nonpathogenic in humans. It has been shown to be oncolytic by its ability to replicate in transformed cells but not in normal cells. Reovirus has been shown to exert significant antitumor effects in both preclinical in vitro and in...
Genetically Engineered Salmonella typhimurium for Targeted Cancer Therapy
Published in Gene Therapy of Cancer
Gene therapy using Salmonella has several possible advantages compared with other gene therapeutic tools, and Salmonella can be engineered according to the specific requirements of effective cancer therapy. As a delivery vector, Salmonella has been applied to gene therapy via three delivery routes: (1) the direct transfer of genes, (2) the delivery...
Ethics in Translational Gene Transfer Research
Published in Gene Therapy of Cancer
The clinical translation of anticancer gene transfer research raises ethical questions not adequately addressed by the basic framework of research regulation. These ethical challenges involve (1) knowing when to transition from preclinical to clinical research, (2) how to think about trial design, and (3) how to enroll patient subjects while avoidi...
Therapeutic Efficacy and Systemic Antitumor T Cell Immunity Induced by RheoSwitch-Regulated IL-12 Expression after Intra...
Published in Gene Therapy of Cancer
Interleukin-12 (IL-12) is a potent immunostimulatory cytokine that activates the innate and adaptive cellular immune system and has shown significant therapeutic activity in preclinical models, but severe toxicity of systemically administered IL-12 in cancer patients has limited clinical utilization. Direct delivery into the tumor, along with regul...
Front-matter
Published in Gene Therapy of Cancer
Section II. Oncolytic Viruses
Published in Gene Therapy of Cancer
